Induced pluripotent stem cells are a type of pluripotent stem cell that can be created from differentiated (“adult”) cells. iPSCs are increasingly being explored for applications within drug development and discovery. This is because patient-derived somatic cells (for example, fibroblasts) can be reprogrammed to produce iPSCs that have disease-specific genetic aberrations. These cells can then be differentiated into the disease-affected cell type (for example, neurons in neurodegenerative diseases). [Read more…]
SERAXIS Inc. publishes clinical trial considerations for a type 1 diabetes stem cell-derived therapy
GERMANTOWN, Md., Nov. 12, 2018 — SERAXIS Inc., a rapidly growing regenerative medicine company today announced the publication of important trial considerations for SR-01, its pluripotent stem cell-derived islet therapy for insulin-dependent diabetes.
An analysis of islet transplant trials registered on clinicaltrials.gov was conducted with the goal of extracting insights to apply in the study design of SERAXIS lead candidate, SR-01 for the treatment of type 1 diabetes. The results of this analysis were published this week in Stem Cells Translational Medicine (doi:10.1002/sctm.18-0156). SR-01 is a combination therapy of insulin-producing cells encapsulated in the retrievable biocompatible SeraGraftTM device, designed to prevent immune system access to the cells after implantation. [Read more…]
Cynata’s “Major Breakthrough” in MSC Manufacturing – Unlimited Quantities, Uniform Batches, Single Donor, & Low Cost
For years, it has been clear that mesenchymal stem cells (MSCs) are a leading type of stem cell being investigated for therapeutic applications, as they have the potential to treat a wide range of acute and degenerative diseases. In addition to secreting factors that can stimulate tissue repair, MSCs can substantially alter their microenvironment, exerting effects that are both anti-inflammatory and anti-fibrotic.
MSCs are also advantageous over other stem cells types, because they avoid the ethical issues that surround embryonic stem cell research and appear to be immuno-privileged. Importantly, MSCs also well-suited for use in the exponential growth area of 3D printing, because of their unusual capacity to form structural tissues. [Read more…]
Cynata Therapeutics to Test Proprietary MSC Manufacturing Process in GvHD Clinical Trial
Cynata Announces First Clinical Study Utilizing MSCs Manufactured by Cymerus™ Platform
Cynata Therapeutics, a stem cell and regenerative medicine company listed on the Australian stock exchange (ASX: CYP), released major news today by announcing that mesenchymal stem cells produced using its Cymerus™ manufacturing platform will be utilized in a Phase 1 clinical study involving patients with steroid-refractory GvHD.
The Clinical Trial Company Ltd was identified as the contract research organization (CRO) that Cynata has engaged to conduct the study. [Read more…]
Parkinson’s Disease Treatment Using Reprogrammed Stem Cells
Anyone who has ever watched a friend or loved one succumb to the slow degradation of Parkinson’s disease will understand the urge to cure it. Read on to learn more about how stem cells could be a possible treatment option for Parkinson’s disease.
In this article:
- « Previous Page
- 1
- …
- 51
- 52
- 53
- 54
- 55
- …
- 78
- Next Page »